What is PolyPid?
PolyPid Ltd. is a late-stage biopharmaceutical company dedicated to enhancing surgical results through its proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology. This platform enables the controlled, prolonged release of active pharmaceutical ingredients (APIs) over extended periods, ranging from days to months. The company's lead candidate, D-PLEX100, is currently undergoing Phase 3 clinical trials for the prevention of surgical site infections in abdominal and sternal bone procedures. Furthermore, PolyPid is exploring the therapeutic potential of its OncoPLEX technology for treating solid tumors, with an initial focus on glioblastoma.
How much funding has PolyPid raised?
PolyPid has raised a total of $139.9M across 8 funding rounds:
Series A
$2.2M
Series B
$10.9M
Series C
$8.3M
Series D
$22M
Private Equity
$5.3M
Series E
$50M
Debt
$14.5M
Stock/Share Issuance
$26.7M
Series A (2011): $2.2M, investors not publicly disclosed
Series B (2014): $10.9M, investors not publicly disclosed
Series C (2015): $8.3M supported by Financiere Saint James and GUIBOR
Series D (2016): $22M featuring Aurum Ventures Private and Shavit Capital
Private Equity (2016): $5.3M backed by Xenia Venture Capital
Series E (2019): $50M with participation from Undisclosed
Debt (2024): $14.5M, investors not publicly disclosed
Stock/Share Issuance (2025): $26.7M, investors not publicly disclosed
Key Investors in PolyPid
Aurum Ventures Private
Aurum Ventures is a specialized real estate investment and asset management company headquartered in Mumbai, India. It focuses on developing, operating, and owning high-quality real estate assets through its in-house teams, targeting long-life assets with high potential for value creation.
Shavit Capital
Shavit Capital is an investment practice founded in 2008 that specializes in late-stage investments in Israeli and Israeli-related companies. With over $500 million under management across five private equity funds, the firm focuses on companies with proven technologies, products, markets, and strong management teams.
Xenia Venture Capital
Xenia Venture Capital is a publicly traded hi-tech investment company on the Tel Aviv Stock Exchange, primarily focused on investing in high tech and med tech sectors in Israel. The company specializes in life science investments and operates a technological incubator, VLX, in partnership with the Israel Innovation Authority.
What's next for PolyPid?
The recent major strategic investment signals PolyPid's progression into a critical scaling phase. This financing is expected to accelerate the advancement of D-PLEX100 through its final clinical trials and support the preclinical development of OncoPLEX. The company's focus on addressing significant unmet needs in surgical site infection prevention and oncology positions it for substantial growth and potential market disruption. Future endeavors will likely involve navigating regulatory pathways and preparing for commercialization, leveraging this substantial backing to solidify its market presence.
See full PolyPid company page
